new-recommended-broker-banner new-recommended-broker-banner

Midatech Pharma (MTP) Stock Jump 35%, Here’s Why…

Updated: 19 Oct 2020

US-listed shares of biotechnology company Midatech Pharma (NASDAQ: MTP) have surged premarket after the company announced positive results from its Phase 1 study in patients with Diffuse Intrinsic Pontine Glioma (DIPG).

The primary endpoint of the study into Midatech's MTX110 drug was to determine the dosage that will be used in Phase 2 trials in patients with DIPG.

The company said that seven patients were involved in the Phase 1 study and that three patients remain alive, although, survival was not an endpoint and there can be no conclusions drawn on the impact of the drug on survival rates. 

new-recommended-broker-banner

“DIPG is a devastating pediatric brain cancer with limited treatment options and very poor outcomes. The overall survival data from this Phase I study are encouraging, although further study of MTX110 in DIPG is required to establish whether it can make a difference to these patients and their families,” said Steve Damment, Midatech's Executive Vice President of R&D. 

Midatech's stock price is currently trading 37.50% higher premarket on Monday at $2.75 per share after Friday's close at $2. Its London-listed shares have rallied 22% to 40.6p. 

PEOPLE WHO READ THIS ALSO VIEWED:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .